Last reviewed · How we verify
DSXS topical
DSXS is a topical formulation designed to deliver active pharmaceutical ingredients to skin lesions or dermatological conditions through enhanced penetration.
DSXS is a topical formulation designed to deliver active pharmaceutical ingredients to skin lesions or dermatological conditions through enhanced penetration. Used for Dermatological indication (specific indication not publicly disclosed).
At a glance
| Generic name | DSXS topical |
|---|---|
| Also known as | active, Active |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
DSXS appears to be a proprietary topical delivery system developed by Sun Pharmaceutical, likely utilizing a novel formulation technology to improve skin penetration and bioavailability of its active ingredient(s). The specific molecular mechanism depends on the active pharmaceutical component, which is not publicly disclosed in available sources. As a Phase 3 topical agent, it is being evaluated for efficacy and safety in dermatological applications.
Approved indications
- Dermatological indication (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis (PHASE3)
- Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product (PHASE2)
- Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis (PHASE3)
- An Open Label, Safety Study to Assess the Potential for Adrenal Suppression. (PHASE2)
- Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis (PHASE2)
- Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis (PHASE3)
- Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis (PHASE3)
- Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DSXS topical CI brief — competitive landscape report
- DSXS topical updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI